Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2013 - 2026)

Amphastar Pharmaceuticals has reported EPS (Basic) for 14 years, with the latest figure at $0.7 in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 5.21% year-over-year to $0.7 in Q2 2026; TTM through Jun 2026 was $1.91, a 27.01% decrease from a year earlier, with the FY2025 full-year figure at $2.2, down 28.08% from the prior year.
• EPS (Basic) was $0.7 for Q2 2026 at Amphastar Pharmaceuticals, up from $0.14 in the prior quarter.
• The five-year high for EPS (Basic) was $1.02 in Q3 2023, with the low at $0.14 in Q1 2026.
• Average EPS (Basic) over 5 years is $0.6, with a median of $0.58 recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EPS (Basic) surged 522.27% in 2022, then slumped 73.31% in 2026.
• Over 5 years, EPS (Basic) stood at $0.6 in 2022, then advanced by 14.77% to $0.69 in 2023, then fell by 21.66% to $0.54 in 2024, then rose by 15.81% to $0.63 in 2025, then rose by 10.83% to $0.7 in 2026.
• The last three EPS (Basic) figures came in at $0.7 (Q2 2026), $0.14 (Q1 2026), and $0.63 (Q4 2025), per Business Quant data.